Cytotoxicity and activation of CB1954 in a human tumour cell line
- 1 May 1991
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 41 (9) , 1293-1298
- https://doi.org/10.1016/0006-2952(91)90100-j
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Activation of prodrugs by antibody‐enzyme conjugates: a new approach to cancer therapyThe FASEB Journal, 1990
- The First Bagshawe lecture: Towards generating cytotoxic agents at cancer sitesBritish Journal of Cancer, 1989
- The nitroreductase enzyme in walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)Biochemical Pharmacology, 1988
- A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in walker carcinoma cellsBiochemical Pharmacology, 1988
- Rapid colorimetric assay for cell growth and survivalJournal of Immunological Methods, 1986
- CB 1954 revisitedCancer Chemotherapy and Pharmacology, 1986
- Selective inhibition of ribonucleotide reductase by the monofunctional alkylating agent 5(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954)Biochemical Pharmacology, 1980
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970
- Tumour-growth inhibitorynitrofphenylaziridines and related compounds structure-activity relationshipsChemico-Biological Interactions, 1969
- 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256Biochemical Pharmacology, 1969